Red blood cell alloimmunization in transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

Transfusion

Volumn 53, Issue 4, 2013, Pages 710-715

  Sanz, Cristina ^a   Nomdedeu, Meritxell ^a   Belkaid, Mohamad ^a   Martinez, Irene ^a   Nomdedeu, Benet ^a   Pereira, Arturo ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ERYTHROCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOIMMUNIZATION; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; QUANTITATIVE ANALYSIS; RED BLOOD CELL ALLOIMMUNIZATION; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ISOANTIBODIES; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; POISSON DISTRIBUTION; REGRESSION ANALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 84876102591     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03819.x     Document Type: Article

References (25)

1. Tefferi A, Vardiman JW,. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-85.
2. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF,. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
3. Stone RM,. How I treat patients with myelodysplastic syndromes. Blood 2009; 113: 6296-303.
4. Arriaga F, Bonanad S, Larrea L, de la Rubia J, Lõpez F, Sanz MA, Sanz G, Marty ML,. Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis. Sangre (Barc) 1995; 40: 177-80. [in Spanish].
5. Stiegler G, Sperr W, Lorber C, Fabrizii V, Höcker P, Panzer S,. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol 2001; 80: 330-3.
6. Schonewille H, de Vries RR, Brand A,. Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion 2009; 49: 453-7.
7. Vardiman JW, Harris NL, Brunning RD,. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
8. Coviello VBN,. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4: 103-12.
9. Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ,. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 2007; 83: 1586-92.
10. Sirchia G, Zanella A, Parravicini A, Morelati F, Rebulla P, Masera G,. Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion 1985; 25: 110-2.
11. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C,. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58: 50-5.
12. Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, Shaigan M, Toolabi A, Salahmand M,. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011; 28: 479-85.
13. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, van der Bom JG,. Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012; 102: 144-9.
14. Garraty G,. Autoantibodies induced by blood transfusion. Transfusion 2004; 44: 5-9.
15. Novaretti MC, Sopelete CR, Velloso ER, Rosa MF, Dorlhiac-Llacer PE, Chamone DA,. Immunohematological findings in myelodysplastic syndrome. Acta Haematol 2001; 105: 1-6.
16. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A,. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987; 52: 95-8.
17. Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD,. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994; 34: 562-9.
18. Castro O, Sandler SG, Houston-Yu P, Rana S,. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion 2002; 42: 684-90.
19. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V,. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002; 42: 37-43.
20. Blumberg N, Ross K, Avila E, Peck K,. Should chronic transfusions be matched for antigens other than ABO and Rho(D)? Vox Sang 1984; 47: 205-8.
21. Ness PM,. To match or not to match: the question for chronically transfused patients with sickle cell anemia. Transfusion 1994; 34: 558-60.
22. Jungbauer C, Hobel CM, Schwartz DWM, Mayr WR,. High-throughput multiplex PCR genotyping for 35 red blood cell antigens in blood donors. Vox Sang 2012; 102: 234-42.
23. Schonewille H, Brand A,. Alloimmunization to red blood cell antigens after universal leucodepletion. A regional multicentre retrospective study. Br J Haematol 2005; 129: 151-6.
24. Sanz C, Ghita G, Franquet C, Martínez I, Pereira A,. Red-blood-cell alloimmunization and female sex predict the presence of HLA antibodies in patients undergoing liver transplant. Vox Sang 2010; 99: 261-6.
25. Rozman P, Dovc T, Gassner C,. Differentiation of autologous ABO, RHD, RHCE, KEL, JK, and FY blood group genotypes by analysis of peripheral blood samples of patients who have recently received multiple transfusions. Transfusion 2000; 40: 936-42.